Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Pharmaceutical Drug Export from Russia (November 2017)

Wednesday, January 10, 2018

By the first 11 months of 2017, the exports, excluding exports to EAEU countries, have amounted to 19 bln RUB (including customs duties), which is only 0.4% higher than that of the same period of 2016 (in RUB). However, the positive dynamics alone is somewhat optimistic. The results between January and October 2017 were much more depressing, with the long-term growth rate amounting to -2.2%.

The hard work of exporters in November 2017 helped to reverse the situation. In November, Russia exported 2.3 bln RUB worth of pharmaceutical drugs, with a 23% increase in monetary terms. While not record-worthy, the results are still impressive. Russian exports had shown a better progress only in January 2017, with a 58% increase.

In November 2017, the export volume in physical terms amounted to 70.8 mln units, which is 22% more than in 2016. Over the year, the total export volume in physical terms has been rather good, though. While there have been falls, such as in February when the export volume in physical terms decreased by 38%, the total export volume rate over the past 11 months amounts to 7.3%. Since January, Russia has exported 536.4 mln units of pharmaceutical drugs.

Ukraine (DPR and LPR) still has the biggest share in Russian pharmaceuticals export in physical terms, while Latvia has shown the biggest dynamics among the top 5 main export destinations. Between January and November 2017, Latvia imported 614 trademarks produced by more than 200 pharmaceutical companies from Russia. Stada has the biggest share in Russian drug export to Latvia (almost one-third), having exported 59 pharmaceutical trademarks, with Levomekol and Vitaprost being the most exported ones. Feron came second, with its Viferon having a 100 times increase in export.

Read more about pharmaceutical drug import to Russia (October performance) here: http://rncph.com/news/27_11_2017

Volumes and dynamics of pharmaceutical drug export from Russia, excluding EAEU countries (January – November 2017)

Share: